$TBPH
Theravance Biopharma Inc

2022 Q3 Form 10-Q Financial Statement

#000155837022012666 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $12.45M $11.05M $13.20M
YoY Change -5.63% -14.43% -7.44%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.28M $16.99M $19.12M
YoY Change -23.58% -34.5% -37.41%
% of Gross Profit
Research & Development $9.867M $15.57M $23.25M
YoY Change -77.44% -69.52% -65.6%
% of Gross Profit
Depreciation & Amortization $655.0K $1.261M $1.141M
YoY Change -59.69% -9.02% -25.91%
% of Gross Profit
Operating Expenses $26.65M $37.93M $51.70M
YoY Change -60.11% -50.76% -47.33%
Operating Profit -$14.20M -$26.88M -$38.50M
YoY Change -73.51% -58.07% -54.11%
Interest Expense $1.545M $11.88M $11.66M
YoY Change -86.84% 2.34% -1.84%
% of Operating Profit
Other Income/Expense, Net $2.758M $2.440M -$375.0K
YoY Change -1761.45% 108.37% 60.26%
Pretax Income -$16.02M -$8.196M -$25.42M
YoY Change -54.63% -84.43% -68.0%
Income Tax $0.00 -$5.000K $500.0K
% Of Pretax Income
Net Earnings $916.6M -$8.191M -$25.95M
YoY Change -2696.1% -84.37% -67.44%
Net Earnings / Revenue 7361.91% -74.13% -196.62%
Basic Earnings Per Share $12.14 -$0.11 -$0.34
Diluted Earnings Per Share $12.14 -$0.11 -$0.65
COMMON SHARES
Basic Shares Outstanding 76.43M 76.27M 75.25M
Diluted Shares Outstanding 75.52M 76.27M 75.25M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $486.8M $132.9M $147.5M
YoY Change 125.16% -49.86% -29.74%
Cash & Equivalents $418.5M $87.29M $94.37M
Short-Term Investments $68.29M $45.56M $53.15M
Other Short-Term Assets $10.77M $9.391M $9.284M
YoY Change -53.54% -66.78% -67.76%
Inventory
Prepaid Expenses
Receivables $14.11M $12.49M $12.28M
Other Receivables $0.00 $0.00 $35.56M
Total Short-Term Assets $511.7M $154.7M $204.6M
YoY Change 72.2% -53.56% -30.18%
LONG-TERM ASSETS
Property, Plant & Equipment $11.88M $12.53M $13.24M
YoY Change -25.74% -24.43% -21.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $148.3M $94.11M
YoY Change -100.0% 313.85% 384.12%
Other Assets $4.866M $3.303M $3.194M
YoY Change 47.59% 149.28% 38.63%
Total Long-Term Assets $251.8M $206.0M $150.7M
YoY Change 137.67% 114.46% 83.73%
TOTAL ASSETS
Total Short-Term Assets $511.7M $154.7M $204.6M
Total Long-Term Assets $251.8M $206.0M $150.7M
Total Assets $763.5M $360.8M $355.4M
YoY Change 89.4% -15.96% -5.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.337M $3.074M $1.510M
YoY Change -40.03% -71.28% -77.9%
Accrued Expenses $16.22M $29.53M $33.58M
YoY Change -61.15% -32.58% -44.31%
Deferred Revenue $24.00K $24.00K $98.00K
YoY Change -99.17% -99.58% -98.72%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $9.012M
YoY Change -100.0% -100.0% -22.97%
Total Short-Term Liabilities $142.1M $32.62M $44.20M
YoY Change 115.08% -51.4% -48.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $624.7M $612.5M
YoY Change -100.0% 3.67% 1.67%
Other Long-Term Liabilities $1.657M $2.404M $2.428M
YoY Change -36.49% 31.15% 17.98%
Total Long-Term Liabilities $1.657M $2.404M $2.428M
YoY Change -36.49% 31.15% 17.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $142.1M $32.62M $44.20M
Total Long-Term Liabilities $1.657M $2.404M $2.428M
Total Liabilities $143.8M $35.03M $46.63M
YoY Change 109.33% -49.21% -47.34%
SHAREHOLDERS EQUITY
Retained Earnings -$843.5M -$1.760B -$1.752B
YoY Change -50.2% 6.12% 9.07%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $480.6M -$349.8M -$351.5M
YoY Change
Total Liabilities & Shareholders Equity $763.5M $360.8M $355.4M
YoY Change 89.4% -15.96% -5.26%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income $916.6M -$8.191M -$25.95M
YoY Change -2696.1% -84.37% -67.44%
Depreciation, Depletion And Amortization $655.0K $1.261M $1.141M
YoY Change -59.69% -9.02% -25.91%
Cash From Operating Activities -$22.14M -$14.73M -$26.07M
YoY Change -51.29% -70.6% -62.69%
INVESTING ACTIVITIES
Capital Expenditures $57.00K -$113.0K -$250.0K
YoY Change -105.49% -26.14% -85.88%
Acquisitions
YoY Change
Other Investing Activities $1.075B $7.628M $32.17M
YoY Change -3194.18% -78.77% -72.13%
Cash From Investing Activities $1.075B $7.515M $31.92M
YoY Change -3104.52% -78.99% -71.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -722.0M 140.0K -1.448M
YoY Change 31484.69% -99.87% -87.17%
NET CHANGE
Cash From Operating Activities -22.14M -14.73M -26.07M
Cash From Investing Activities 1.075B 7.515M 31.92M
Cash From Financing Activities -722.0M 140.0K -1.448M
Net Change In Cash 331.2M -7.075M 4.407M
YoY Change -496.58% -107.78% -86.46%
FREE CASH FLOW
Cash From Operating Activities -$22.14M -$14.73M -$26.07M
Capital Expenditures $57.00K -$113.0K -$250.0K
Free Cash Flow -$22.19M -$14.62M -$25.82M
YoY Change -50.02% -70.74% -62.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.03
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76270000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65669000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75761000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65085000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76427000
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74435000
dei Entity Central Index Key
EntityCentralIndexKey
0001583107
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76270000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65669000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75761000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65085000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.03
CY2022Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36033
dei Entity Registrant Name
EntityRegistrantName
THERAVANCE BIOPHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
KY
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1226628
dei Entity Address Address Line1
EntityAddressAddressLine1
PO Box 309
dei Entity Address Address Line2
EntityAddressAddressLine2
Ugland House, South Church Street
dei Entity Address City Or Town
EntityAddressCityOrTown
George Town, Grand Cayman
dei Entity Address Country
EntityAddressCountry
KY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
KY1-1104
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
808-6000
dei Security12b Title
Security12bTitle
Ordinary Share $0.00001 Par Value
dei Trading Symbol
TradingSymbol
TBPH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76427244
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87292000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
89959000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
45558000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
83506000
CY2022Q2 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
12488000
CY2021Q4 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
14065000
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
43534000
CY2022Q2 tbph Prepaid Clinical And Development Services
PrepaidClinicalAndDevelopmentServices
2311000
CY2021Q4 tbph Prepaid Clinical And Development Services
PrepaidClinicalAndDevelopmentServices
10245000
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7080000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
8561000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
154729000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
249870000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12531000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13657000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
41112000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
39690000
CY2022Q2 us-gaap Equity Method Investments
EquityMethodInvestments
148250000
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
67537000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
836000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
837000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3303000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3228000
CY2022Q2 us-gaap Assets
Assets
360761000
CY2021Q4 us-gaap Assets
Assets
374819000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3074000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3098000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6958000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12796000
CY2022Q2 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
7627000
CY2021Q4 tbph Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
2898000
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
3990000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
503000
CY2021Q4 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
17010000
CY2022Q2 tbph Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
6052000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3940000
CY2021Q4 tbph Non Recourse Debt Due2035 Current
NonRecourseDebtDue2035Current
16940000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2624000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
24000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
98000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2275000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1304000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
32624000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
58587000
CY2022Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
228571000
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
228035000
CY2022Q2 tbph Non Recourse Debt Due2035 Noncurrent
NonRecourseDebtDue2035Noncurrent
396125000
CY2021Q4 tbph Non Recourse Debt Due2035 Noncurrent
NonRecourseDebtDue2035Noncurrent
371359000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
50642000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
52681000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
204000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
310000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2404000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2420000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76427000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74435000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1410415000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1387469000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-45000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1760180000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1726043000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-349809000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-338573000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
360761000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
374819000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11050000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12914000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24246000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27171000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15571000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51093000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38824000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
118692000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16986000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25931000
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
1594000
us-gaap Restructuring Charges
RestructuringCharges
10918000
tbph Transaction Related Legal Expenses
TransactionRelatedLegalExpenses
5057000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34828000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
56481000
CY2022Q2 tbph Transaction Related Legal Expenses
TransactionRelatedLegalExpenses
3778000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
37929000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
77024000
us-gaap Operating Expenses
OperatingExpenses
89627000
us-gaap Operating Expenses
OperatingExpenses
175173000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26879000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-64110000
us-gaap Operating Income Loss
OperatingIncomeLoss
-65381000
us-gaap Operating Income Loss
OperatingIncomeLoss
-148002000
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
28127000
CY2021Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
21926000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
53237000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
38473000
CY2022Q2 us-gaap Interest Expense
InterestExpense
11884000
CY2021Q2 us-gaap Interest Expense
InterestExpense
11612000
us-gaap Interest Expense
InterestExpense
23539000
us-gaap Interest Expense
InterestExpense
23485000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2440000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1171000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2065000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
937000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8196000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52625000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33618000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-132077000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-220000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
519000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8191000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-52405000
us-gaap Net Income Loss
NetIncomeLoss
-34137000
us-gaap Net Income Loss
NetIncomeLoss
-132084000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-45000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-39000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8208000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52414000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34182000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-132123000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.03
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75761000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76270000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65669000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
91699000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
191400000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
108180000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2862000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14941000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2021Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
727000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-52405000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-300374000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65085000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9709000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14941000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24254000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30773000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-351450000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
487000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9709000
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
347000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8191000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-349809000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-338573000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
487000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24254000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1795000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-45000
us-gaap Net Income Loss
NetIncomeLoss
-34137000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-349809000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-373218000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-303751000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
108180000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2862000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30773000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6320000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-39000
us-gaap Net Income Loss
NetIncomeLoss
-132084000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-300374000
us-gaap Net Income Loss
NetIncomeLoss
-34137000
us-gaap Net Income Loss
NetIncomeLoss
-132084000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
2402000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
2926000
tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
31000
tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
-31000
us-gaap Share Based Compensation
ShareBasedCompensation
24254000
us-gaap Share Based Compensation
ShareBasedCompensation
30773000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
96000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
2721000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1314000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1752000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1866000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
205782000
tbph Gain Loss On Modification Of Lease
GainLossOnModificationOfLease
47000
tbph Equity Method Investments Undistributed Earnings
EquityMethodInvestmentsUndistributedEarnings
37179000
tbph Equity Method Investments Undistributed Earnings
EquityMethodInvestmentsUndistributedEarnings
-2986000
tbph Interest Shortfall On2035 Notes
InterestShortfallOn2035Notes
7372000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
168000
tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-1577000
tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-3648000
tbph Increase Decrease In Prepaid Clinical And Development Services
IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices
-7934000
tbph Increase Decrease In Prepaid Clinical And Development Services
IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices
-4461000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-2619000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1993000
tbph Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-2689000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
145000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-997000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-26000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4026000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-11135000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-33125000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
50000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-74000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-180000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-5852000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
82000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
1718000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-17000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40799000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-119978000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
363000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1923000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
53763000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
40014000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
39439000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
149463000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
108180000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10730000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
487000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2862000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1795000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
6320000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1308000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
93997000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2668000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
123482000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90796000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82300000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88128000
us-gaap Interest Paid Net
InterestPaidNet
15127000
us-gaap Interest Paid Net
InterestPaidNet
22490000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
25000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
12000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</p>
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8191000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-52405000
us-gaap Net Income Loss
NetIncomeLoss
-34137000
us-gaap Net Income Loss
NetIncomeLoss
-132084000
CY2022Q2 tbph Weighted Average Number Of Shares Outstanding Before Forfeitures
WeightedAverageNumberOfSharesOutstandingBeforeForfeitures
76270000
CY2021Q2 tbph Weighted Average Number Of Shares Outstanding Before Forfeitures
WeightedAverageNumberOfSharesOutstandingBeforeForfeitures
65669000
tbph Weighted Average Number Of Shares Outstanding Before Forfeitures
WeightedAverageNumberOfSharesOutstandingBeforeForfeitures
75761000
tbph Weighted Average Number Of Shares Outstanding Before Forfeitures
WeightedAverageNumberOfSharesOutstandingBeforeForfeitures
65199000
tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-114000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76270000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65669000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75761000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65085000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.03
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12336000
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12904000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12915000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14983000
tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.35
CY2022Q2 tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
1543000
CY2021Q2 tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
1260000
tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
3079000
tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
2686000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87292000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
204949000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
836000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
833000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88128000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
205782000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
92308000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
47000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
92261000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
133738000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
133734000
tbph Marketable Securities Maximum Contractual Maturity Period
MarketableSecuritiesMaximumContractualMaturityPeriod
P6M
tbph Marketable Securities Average Contractual Maturity Period
MarketableSecuritiesAverageContractualMaturityPeriod
P4M
CY2022Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
45557000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
47000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
45557000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
47000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
35017000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
5000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
35017000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
5000
CY2022Q2 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
0
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
624696000
CY2021Q3 tbph Share Based Compensation Allocation Of Recognized Period Costs Capitalized Reversed Amount
ShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedReversedAmount
800000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
1700000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
500000
CY2022Q2 us-gaap Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries
DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries
0
CY2021Q3 tbph Percentage Of Reduction In Workforce
PercentageOfReductionInWorkforce
0.75
CY2021Q4 tbph Percentage Of Reduction In Workforce
PercentageOfReductionInWorkforce
0.75
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
1600000
us-gaap Restructuring Charges
RestructuringCharges
10900000
us-gaap Restructuring Charges
RestructuringCharges
31100000
CY2022Q2 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
17600000
tbph Non Cash Charges Related To Modification Of Equity Awards For Terminated And Remaining Employee
NonCashChargesRelatedToModificationOfEquityAwardsForTerminatedAndRemainingEmployee
14300000
tbph Restructuring And Related Expenses Recognized Percentage
RestructuringAndRelatedExpensesRecognizedPercentage
0.97
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
9550000
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
6275000
us-gaap Payments For Restructuring
PaymentsForRestructuring
15233000
CY2022Q2 us-gaap Restructuring Reserve
RestructuringReserve
592000
CY2022Q2 tbph Transaction Related Legal Expenses
TransactionRelatedLegalExpenses
3800000
tbph Transaction Related Legal Expenses
TransactionRelatedLegalExpenses
5100000

Files In Submission

Name View Source Status
0001558370-22-012666-index-headers.html Edgar Link pending
0001558370-22-012666-index.html Edgar Link pending
0001558370-22-012666.txt Edgar Link pending
0001558370-22-012666-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tbph-20220630.xsd Edgar Link pending
tbph-20220630x10q.htm Edgar Link pending
tbph-20220630xex31d1.htm Edgar Link pending
tbph-20220630xex31d2.htm Edgar Link pending
tbph-20220630xex32.htm Edgar Link pending
tbph-20220630_cal.xml Edgar Link unprocessable
tbph-20220630_pre.xml Edgar Link unprocessable
tbph-20220630_lab.xml Edgar Link unprocessable
tbph-20220630x10q_htm.xml Edgar Link completed
tbph-20220630_def.xml Edgar Link unprocessable